BridgeBio Pharma annual current ratio
2018
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Current Ratio Growth & History (BBIO)
BridgeBio Pharma's current ratio was 2.77 for fiscal 2025.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.77 | −1.90 | −40.65% |
| 2024 | 2024-12-31 | 4.67 | 1.35 | +40.58% |
| 2023 | 2023-12-31 | 3.32 | −1.20 | −26.54% |
| 2022 | 2022-12-31 | 4.52 | −2.06 | −31.32% |
| 2021 | 2021-12-31 | 6.58 | −0.14 | −2.08% |
| 2020 | 2020-12-31 | 6.72 | −2.70 | −28.63% |
| 2019 | 2019-12-31 | 9.42 | −4.25 | −31.10% |
| 2018 | 2018-12-31 | 13.67 | — | — |
BridgeBio Pharma quarterly current ratio
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.23 | −3.96 | −76.34% |
| Q1 2026 | 2026-03-31 | 1.52 | −3.05 | −66.73% |
| Q4 2025 | 2025-12-31 | 2.77 | −1.90 | −40.65% |
| Q3 2025 | 2025-09-30 | 3.88 | 0.68 | +21.35% |
| Q2 2025 | 2025-06-30 | 5.19 | 0.60 | +13.11% |
| Q1 2025 | 2025-03-31 | 4.57 | −0.97 | −17.46% |
| Q4 2024 | 2024-12-31 | 4.67 | 1.35 | +40.58% |
| Q3 2024 | 2024-09-30 | 3.19 | −2.35 | −42.36% |
| Q2 2024 | 2024-06-30 | 4.59 | 0.66 | +16.67% |
| Q1 2024 | 2024-03-31 | 5.54 | −0.18 | −3.22% |
| Q4 2023 | 2023-12-31 | 3.32 | −1.20 | −26.54% |
| Q3 2023 | 2023-09-30 | 5.54 | 0.15 | +2.83% |
| Q2 2023 | 2023-06-30 | 3.93 | −1.53 | −28.05% |
| Q1 2023 | 2023-03-31 | 5.72 | −1.20 | −17.35% |
| Q4 2022 | 2022-12-31 | 4.52 | −2.06 | −31.32% |
| Q3 2022 | 2022-09-30 | 5.39 | −1.29 | −19.29% |
| Q2 2022 | 2022-06-30 | 5.46 | −1.43 | −20.79% |
| Q1 2022 | 2022-03-31 | 6.92 | −3.05 | −30.61% |
| Q4 2021 | 2021-12-31 | 6.58 | −0.14 | −2.08% |
| Q3 2021 | 2021-09-30 | 6.68 | −3.17 | −32.19% |
| Q2 2021 | 2021-06-30 | 6.90 | −2.41 | −25.86% |
| Q1 2021 | 2021-03-31 | 9.98 | −4.27 | −29.98% |
| Q4 2020 | 2020-12-31 | 6.72 | −2.70 | −28.63% |
| Q3 2020 | 2020-09-30 | 9.85 | −4.16 | −29.69% |
| Q2 2020 | 2020-06-30 | 9.30 | — | — |
| Q1 2020 | 2020-03-31 | 14.25 | — | — |
| Q4 2019 | 2019-12-31 | 9.42 | −4.25 | −31.10% |
| Q3 2019 | 2019-09-30 | 14.00 | — | — |
| Q4 2018 | 2018-12-31 | 13.67 | — | — |
BridgeBio Pharma current ratio trends
Over the last five fiscal years, BridgeBio Pharma's current ratio decreased from 6.72 to 2.77, a change of −3.95. The latest reported quarter, Q2 2026, shows 1.23.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma source filings ↗Community posts
BridgeBio’s Attruby sales expand as a one-time milestone boosts quarterly revenue
BridgeBio ($BBIO) reported third-quarter 2026 revenue of $353.2 million, compared with $120.7 million a year earlier. US Attruby sales reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year ...
